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1. Introduction 
The basic principle of current gene therapy is to deliver genetic material to a population of 
cells in the body, thereby preventing a disease or improving the clinical status of a patient. 
One of key factors for successful gene therapy is the development of effective delivery. To 
date, a plethora of gene delivery systems, termed “vectors”, have been developed, and these 
fall into two broad categories: nonviral and viral vectors. Basically, the nonviral vector 
systems involve delivery of naked DNA or RNA into target cells with the aid of physical or 
chemical mediators such as cationic lipids. In terms of their simplicity, producibility, and 
immunogenicity, nonviral vector systems hold advantages over viral vector systems. 
However, in terms of the efficiency of gene delivery and expression, the viral vector systems 
are considered as more ideal (Goverdhana et al., 2005; Verma & Weitzman, 2005). 
Although a variety of gene-transfer vectors based on RNA and DNA viruses have been 
adapted to deliver foreign genes to target cells in vitro and in vivo, most viral vectors are 
derived from adenoviruses and retroviruses. Adenoviruses are DNA viruses that are 
characterized by a nonenveloped icosahedral virion containing a double-stranded linear 
DNA genome of 30-36 kb (Berk, 2007). The virus enters the target cell by endocytosis via 
interactions between the fiber protein on the virion and the adenoviral receptor on the cell 
surface followed by the subsequent binding of a second virion protein, penton, to a 
cellular integrin protein. Inside the cell, uncoating of virions takes place in the cytoplasm 
where the viral DNA genome remains associated with a core-derived protein that 
promotes efficient nuclear entry of the viral genome. Within the nucleus, viral DNA exists 
as an episome, consequently replication of the viral genome takes place in the nucleus 
(Leopold et al., 1998). Adenovirus genes are mainly divided into two classes, early and 
late, based on the time of expressions during the replication. Many of the recombinant 
adenovirus vectors used in gene transfer have been generated by the deletion and/or 
mutation of the early genes which are mostly involved in the activation of other viral 
genes, replication of the viral DNA genome, modulation of host immune responses, and 
inhibition of host cell apoptosis (Armentano et al., 1995; Armentano et al., 1999; Bett et al., 
1994; Brough et al., 1997; Danthinne& Imperiale, 2000; Fallaux et al., 1996; Flint & Shenk, 
1997; Gao et al., 1996; Graham et al., 1977; Imler et al., 1996; Wang et al., 1995; Yeh et al., 
1996). More recently, the helper-dependent adenoviral vectors, so-called “gutted” vectors, 
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have been created by removing most of the viral genes from adenoviral genome 
(Kochanek et al., 1996; Lowenstein et al., 2002; Ng et al., 2001; Parks et al., 1996; Umana et 
al., 2001). Although the gutted vectors need to employ a helper virus that provides all the 
viral proteins necessary for vector production (Kochanek et al., 1996; Lowenstein et al., 
2002; Ng et al., 2001; Parks et al., 1996; Umana et al., 2001), defect of all the viral-coding 
sequences theoretically allows the cloning of large DNA fragments up to 36 kb 
(Goverdhana et al., 2005). Although their tropism for the airway epithelial cells meant that 
adenovirus-based vectors were originally developed for the treatment of genetic lung 
diseases such as cystic fibrosis (Flotte et al., 2007), one of the major advantages of 
adenoviral vectors is that they are able to infect a wide variety of cells in a cell-cycle 
independent manner (Bergelson et al., 1997; Cullen, 2001; Tomko et al., 1997; Whittaker et 
al., 2000). However, one limitation is the persistence of transgene expression; adenoviral 
vector-mediated gene expression is short-term, ranging from two weeks to a few months. 
Thus, this vector is more appropriate for use in treatment of diseases that require high 
and transient gene expression (Robbins & Ghivizzani, 1998). 
In contrast with adenoviral vectors, retroviruses have a substantial advantage as vectors for 
the sustained expression of a transgene in target cells (Verma & Weitzman, 2005). 
Retroviruses are enveloped RNA viruses belonging to the Retroviridae family. The retroviral 
particle contains two copies of linear, positive sense, single-stranded RNA of 7-13 kb in 
length. All members of the Retroviridae family harbors at the minimum three essential genes: 
gag for structural proteins, pol for enzymes, and env for envelope. In the retroviral genome, 
the gag gene is positioned upstream of the pol gene, and the Pol polyprotein is generated as a 
fusion protein with the Gag polyprotein (Gag-Pol). As we shall see in the next section, the 
viral RNA genome is converted into a double-stranded DNA copy by reverse transcriptase 
(RT), a processing product of Pol, soon after the entry into the target cell (reverse 
transcription). Subsequently, the viral DNA is transported to the nucleus and covalently 
joined with cellular chromatin. This joining step is called integration and it is catalyzed by 
integrase (IN), another processing product of Pol. The integration step as well as the reverse 
transcription is hallmark of retroviral infection. Once integrated, the viral DNA serves as a 
template for the transcription of viral genes, enabling sustained gene expression in infected 
cells. The integrated viral DNA also contains cis-acting sequences termed the long terminal 
repeat (LTR) at its termini, which consist of 3’ unique elements (U3), repeat elements (R), 
and 5’ unique elements (U5). The 5’ LTR sequence functions as the promoter sequence for 
gene expression, in which viral RNA transcription is initiated at the U3-R, and the 
transcripts are polyadenylated at the R-U5 boundary of the 3’ LTR. The development of 
retrovirus as a gene transfer vector was first achieved with oncoretroviruses in the 1980s 
(Mann et al., 1983; Miller & Rosman, 1989; Shimotohno & Temin, 1981; Tabin et al., 1982; 
Watanabe & Temin, 1983; Wei et al., 1981); nowadays Moloney murine leukemia virus 
(MoMLV), one of the well characterized oncoretroviruses, is commonly used for therapeutic 
applications (Anderson et al., 1990; Blaese et al., 1993; Guild et al., 1988; Levine& Friedmann, 
1991; Miller, 1992a, b). However, the important limitation of the MoMLV-derived vector is 
its cell cycle dependency: this virus lacks the ability to infect non-dividing cells (Harel et al., 
1981; Hatziioannou & Goff, 2001; Lewis & Emerman, 1994; Miller et al., 1990; Roe et al., 
1993). Unlike the MoMLV, lentiviruses, a separate genus of the Retroviridae family including 
human immunodeficiency virus type-1 (HIV-1), can infect both dividing and non-dividing 
cells (Bukrinsky et al., 1992; Hatziioannou & Goff, 2001; Lewis et al., 1992; Lewis & 
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Emerman, 1994). The ability to infect non-dividing cells is not restricted to in vitro cell 
culture as lentivirus-derived vectors are capable of transducing certain quiescent or 
terminally differentiated cells such as macrophages and microglia (Miyake et al., 1998; 
Naldini et al., 1996; Weinberg et al., 1991). This property makes the lentivirus an attractive 
choice for gene transfer vector (Suzuki & Craigie, 2007). 
It is well known that HIV-1 is the causative agent for acquired immunodeficiency syndrome 
(AIDS). Currently, the standard AIDS treatment, termed highly active antiretroviral therapy 
(HAART), is to use cocktail of antiretroviral drugs that targets different HIV-1 enzymes 
including reverse transcriptase and protease. However, although it successfully causes 
suppression of HIV-1 RNA detected in plasma for a prolonged period of time and dramatic 
decrease of patient mortality (Palella et al., 1998; Volberding & Deeks, 2010), this 
pharmacological therapy is facing problems such as drug resistance and side effects in 
administrated individuals (Meadows & Gervay-Hague, 2006; Richman, 2001). Hence, viral 
vector-based gene therapy should offer a new approach to supplement the need for current 
drug regimens for the treatment of HIV/AIDS (Poluri et al., 2003; Strayer et al., 2005). 
Genetic modification of HIV-susceptible cells or hematopoietic stem cells (HSCs) by 
expressing anti-HIV transgenes should be one of the goals of the HIV gene therapy (Kitchen 
et al., 2011). In this regard, the lentiviral vector has the potential advantage for transduction 
because of its ability to infect quiescent cells including HSC (Miyoshi et al., 1999). However, 
incorporation of anti-HIV genes into an HIV-based lentiviral vector can create problems for 
production of the vector itself; expression of the anti-HIV trans gene in the producer cells 
can interfere with vector production (Banerjea et al., 2003; Li et al., 2003; Mautino & Morgan, 
2002c). One way to avoid this difficulty is to introduce a gene regulatable system in which 
the target transgene is kept silent during vector production and expression is subsequently 
induced on following infection of the vector in target cells. 
Several regulatable gene expression systems have been developed and applied to viral 
vectors including lentiviral vectors (Goverdhana et al., 2005; Weber & Fussenegger, 2004). In 
this chapter, we focus on recent development of the gene-regulatable lentiviral vectors and 
discuss the suitability of the vectors for anti-HIV therapy. 
2. Biology of HIV-1 replication 
2.1 Genomic organization and gene expression 
Lentiviruses, as represented by HIV-1, are also called complex retroviruses, which are 
characterized by a set of additional regulatory and accessory genes encoded in the viral 
genome (Cullen, 1991; Frankel & Young, 1998). In the case of HIV-1, the DNA genome 
converted from the RNA genome is about 9.7 kb and contains nine ORFs; in addition to the 
gag, pol, and env genes that are typical of all retroviruses, there are two regulatory (tat and 
rev) and four accessory (vif, vpr, vpu, and nef) genes (Fig. 1). These protein-coding regions are 
flanked by 5’ and 3’ LTR that are required for reverse transcription, integration, and gene 
expression steps. 
The complexity of HIV-1 is also characterized by its specific pattern of viral gene regulation 
(Kingsman & Kingsman, 1996). The HIV-1 LTR harbors several cis-acting sequences 
required for the initiation of viral RNA expression. The U3 region of the LTR is composed of 
a series of control elements that recruit a variety of transcription factors (Brady & Kashanchi, 
2005), and consequently, transcription of viral RNA initiates at the U3-R junction. However, 
the transcription activity of the U3 is basically low, and trans-acting proteins are required to 
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enhance the viral RNA synthesis from the 5’ LTR. Viral regulatory protein, Tat is one of 
these transactivators (Brady & Kashanchi, 2005). Tat interacts not with DNA, but with an 
RNA bulge of a stem-loop structure formed at the 5’ end of nascent transcripts, which is 
known as the transactivation response region (TAR) (Berkhout et al., 1989; Feng & Holland, 
1988). Binding of Tat to the TAR then recruits an active transcription elongation complex 
consisting of cyclin T1 (CycT1), CDK9, and some other factors (Brady & Kashanchi, 2005). 
Subsequently, CDK9 leads the hyperphosphorylation of the C-terminal domain of RNA 
polymerase II, in turn resulting in a dramatic stimulation of transcriptional processivity 
(Brady & Kashanchi, 2005). 
More than 30 species of RNA are transcribed from the integrated HIV-1 DNA; these fall into 
three size classes of mRNA based on the pattern of splicing: unspliced, partially spliced, and 
multiply spliced RNAs. (Kingsman & Kingsman, 1996; Purcell & Martin, 1993; Schwartz et al., 
1990). The unspliced transcript is full-length RNA (about 9 kb) that is packaged as the viral 
genome into new viral particles but it also functions as mRNA to produce Gag and Gag-Pol 
polyproteins. The partially spliced transcripts (about 4 kb) encode Vif, Vpr, Vpu, and Env 
proteins. At early times after infection, however, the multiply spliced RNAs are predominant, 
and their encoded proteins, Tat, Rev, and Nef are highly produced (Kim et al., 1989).  
 
 
Fig. 1. Organization of the HIV-1 genome. 
2.2 Replication cycle 
HIV-1 infection begins with the binding of the viral envelope (Env) glycoprotein gp120 
(surface envelope protein: SU) to the CD4 receptor molecule on the surface of host cells. 
Consequently, the main target cells for HIV-1 infection are the CD4+ subset of helper T cells 
and monocyte/macrophage lineages (Dalgleish et al., 1984; Landau et al., 1988; Stevenson, 
2003). The gp120-CD4 interaction triggers a conformational change in the gp120 that 
facilitates subsequent binding to a secondary cellular receptor (coreceptor). While most HIV-
1 strains use either the α-chemokine receptor CXCR4 or the β-chemokine receptor CCR5 as 
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the coreceptor, other chemokine receptors or related proteins have been reported to serve as 
coreceptors for HIV-1 infection (Berger et al., 1999). This coreceptor usage is the basis for the 
differential cell-type tropism of HIV-1 strains. Formation of the gp120-CD4-coreceptor 
complex then induces refolding of the gp41 subunit of the Env (transmembrane envelope 
protein: TM), which allows the membrane fusion process between the virus and target cell 
(Melikyan, 2008). 
After penetrating the cell membrane, the viral nucleoprotein core, which contains genomic 
RNA, is released into the cytoplasm, followed by the uncoating of the viral core that is 
required for the formation of the reverse transcription complex (RTC) (Arhel, 2010; 
Bukrinskaya et al., 1998; Fassati & Goff, 2001). Reverse transcription, one of the defining 
steps of retrovirus infection, takes place in the RTC and it is initiated from the 3’ end of the 
tRNALys3 that is annealed to the primer binding site (PBS) near the 5’ end of the viral RNA 
genome. During the reverse transcription reaction, RT firstly synthesizes the minus-strand 
DNA along with the concomitant degradation of the RNA template by its RNase H activity 
(Basu et al., 2008). Subsequent synthesis of plus-strand DNA involves priming from two 
polyprine tracts (PPT), short RNA segments resistant to RNase H digestion, at the 3’ 
terminus (3’ PPT) and the center (central PPT: cPPT) of the HIV-1 genome. Once the 3’ end 
of the plus-strand DNA reaches the 5’ end of the cPPT, DNA synthesis proceeds by 
displacing the existing DNA fragments and stops at a central termination sequence (CTS) in 
the minus-strand DNA, resulting in a 99 bp triple-strand DNA structure in the center of the 
HIV-1 DNA (Arhel, 2010; Charneau et al., 1992; Charneau et al., 1994). 
The newly synthesized full-length viral DNA remains associated with viral and cellular 
proteins in a large nucleoprotein complex called the preintegration complex (PIC) 
(Engelman, 2003). The HIV-1 PIC has been shown to contain RT, IN, matrix (MA), 
nucleocapsid (NC), and Vpr proteins (Lewinski & Bushman, 2005; Suzuki & Craigie, 2007). 
In addition to viral proteins, several cellular proteins have been reported as components of 
the HIV PIC (Suzuki & Craigie, 2007). As mentioned above, unlike many oncoretroviruses, 
HIV-1 is able to infect non-dividing cells. Thus, the HIV-1 PIC is believed to carry 
karyophilic signals that direct transport across an intact nuclear membrane in non-dividing 
cells. Although the molecular mechanisms underlying the active transport of HIV-1 PIC into 
the nucleus is still poorly understood, several viral and cellular factors have been shown to 
be implicated in the nuclear import of the HIV-1 PIC (Fassati, 2006; Suzuki & Craigie, 2007; 
Yamashita & Emerman, 2006). Cell cycle-independent infection of HIV-1 is particularly 
important in the pathogenesis of the virus and the development of HIV-1-based lentiviral 
vectors (Blankson et al., 2002; Kaul et al., 2001; Somia & Verma, 2000). 
Following nuclear transport of the PIC, integration of viral DNA into the host chromatin 
takes place. IN is a key component of the PIC that catalyzes the integration. This reaction 
proceeds via three coordinated steps: 3’ end processing of the viral DNA, joining to the 
target DNA, and repairing of the gaps between viral DNA and target DNA. IN is 
responsible for the 3’ end processing and DNA joining steps, but the gap repair step is likely 
to be carried out by yet-to-be-identified cellular enzymes (Engelman, 2003) (Fig. 2). 
The integrated DNA, called the provirus, is acted upon by cellular transcription factors to 
express viral genes. Early populations of the transcripts are the multiply spliced class of 
mRNA that encodes Tat, Rev, and Nef proteins (Kingsman & Kingsman, 1996). Tat enhances 
production of viral mRNAs by more than two log via interaction with TAR and a cellular 
elongation complex (Brady & Kashanchi, 2005). There is then an increase in the partially 
spiced and unspliced mRNAs along with a concomitant decrease in the multiply spliced 
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mRNAs, which is caused by the accumulation of Rev protein. Rev is also required for the 
nuclear export of partially spliced and unspliced mRNAs. These classes of viral RNAs 
contain a highly structured cis-acting element termed Rev response element (RRE) that is 
located in the env coding region. Rev bears a leucine-rich nuclear export signal (NES) and, 
via association with the RRE, mediates nuclear-to-cytoplasmic transport of the partially 
spliced and unspliced RNAs, resulting in production of Gag, Gag-Pol, Env, and accessory 
proteins (Pollard & Malim, 1998). 
Following the synthesis of the full-length viral RNA genome and the viral proteins, these 
components are assembled together to produce new viruses. In HIV-1, the assembly process 
takes place at the plasma membrane (Ono, 2010). Gag protein plays a central role in the 
formation of virions; this protein is synthesized as a 55 kDa precursor protein for matrix (MA), 
capsid (CA)), and nucleocapsid (NC) proteins. The Gag precursor proteins are rapidly targeted 
to the plasma membrane where they multimerize. Although the multimerization of the Gag is 
sufficient to give rise to virus like particles, incorporation of Gag-Pol proteins is integral to the 
formation of infectious virions (Wu et al., 1997). Gag-Pol is a 160 kDa multidomain protein 
consisting of RT, IN, and protease (PR), and it too relocates to the plasma membrane, where 
Gag and Gag-Pol are assembled into virus particles. In the HIV-1 genome, Gag and Pol are 
encoded by overlapping ORF; Gag-Pol is generated by a ribosomal frameshifting during 
translation of the gag gene. This translation mechanism limits intracellular synthesis of Gag-Pol 
at 10- to 20-fold-lower than Gag (Haraguchi et al., 2010). Env glycoprotein, which is 
synthesized in the rough endoplasmic reticulum (ER), reaches the cell surface and is 
incorporated into virus particles. The MA domain of Gag has been suggested to be important 
for the recruitment of Env into virions (Ono, 2010). Encapsidation of the viral genomic RNA is 
directed by an interaction between the NC domain of Gag and the packaging signal (or ψ-site 
located in the 5’ region of the gag initiation codon. The ψ sequence also acts as a dimerization 
signal for the viral RNA genome. Eventually, the virus particle is pinched off the host cell 
membrane (budding). Recent evidence has revealed that a number of cellular proteins in the 
vacuolar protein sorting (VPS) pathway are involved in the HIV-1 budding process. After 
release from the plasma membrane, virus particles undergo a maturation step, in which Gag 
and Gag-Pol precursor proteins are cleaved by the viral PR to yield the functional mature 
proteins of infectious HIV-1 (Vogt, 1996) (Fig. 2). 
Accessory proteins (i.e. Vif, Vpr, Vpu, and Nef) are dispensable for viral replication in many 
in vitro cell culture systems, but these proteins are likely to be required for efficient 
replication and pathogenicity of HIV-1 in vivo (Malim & Emerman, 2008). 
3. Development of HIV-1-derived lentiviral vectors 
Although retrovirus vectors derived from oncoretroviruses were introduced first, in recent 
years, attention of the viral vector research has been focused on lentiviruses such as HIV-1 and 
equine infectious anemia virus (EIAV) due to their ability to infect non-dividing cells. In 
particular, HIV-1 should be one of the most practical gene transfer vectors for gene therapy 
applications because this is the best studied retrovirus. However, HIV-1 is a human pathogen 
that causes destruction the of CD4+ helper T lymphocytes and the subsequent loss of immune 
competence (Forsman & Weiss, 2008). Therefore, considerable efforts have been devoted to 
develop efficient HIV-1-derived lentiviral vectors with improved biosafety features. 
So far, three different generations of HIV-1-based lentiviral vectors have been established, 
which is based on the level of safety improvements in viral vector production (Fig. 3). 
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Fig. 2. Schematic representation of HIV-1 replication. HIV-1 enters target cells by first 
binding to the CD4 receptor and a coreceptor (CCR5 or CXCR4), this allows fusion between 
the cellular and viral membranes. After entry, the viral nucleoprotein core containing the 
genomic RNA is released into cytoplasm. Reverse transcription takes place in a 
nucleoprotein complex termed the RTC. The synthesis of full-length viral DNA produces an 
integration-competent nucleoprotein complex called the PIC and this nucleoprotein complex 
mediates integration of viral DNA into chromatin. Integrated viral DNA, called the 
provirus, serves as a transcription template for the synthesis of viral mRNA and genomic 
RNA. Following the synthesis of viral proteins, the viral components are assembled together 
to produce new virions, the virus particles then undergo a maturation step to generate 
infectious HIV-1.  
3.1 First-generation lentiviral vectors 
One of the key safety concerns in the use of HIV-derived vectors is the generation of 
replication competent lentiviruses (RCL). Earlier development of lentiviral vectors was 
achieved by transient transfection of human embryonic kidney (HEK293T) cells with three 
separate plasmid DNAs encoding i) the lentiviral vector genome which was composed of the 
wild-type 5’ and 3’ LTR, a part of the gag gene corresponding to the ψ sequence, a part of the 
env gene containing the RRE, an internal promoter, and the desired gene (transfer vector 
plasmid), ii) the HIV-1 genome containing all viral genes with the exception of the env gene 
(packaging plasmid), and iii) the vesicular stomatitis virus G protein (VSV-G) that improves 
the stability and broadens the cellular tropism of lentiviral vectors (Burns et al., 1993; Naldini et 
al., 1996). However, in this vector production system, there is a potential risk for the generation 
of RCL; a recombination event would occur during subsequent reverse transcription in 
transduced cells between two RNAs that are derived from the transfer vector plasmid and the 
packaging plasmid and incidentally copackaged within the same virion (Fig. 3A).  
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Fig. 3. Schematic representation of HIV-1-derived lentiviral vector packaging constructs. The 
first-generation lentiviral vectors (A) are produced by three separate plasmid DNAs 
encoding the vector genome, all HIV-1 genes except for env gene, and Env protein (VSV-G). 
To reduce the potential risk of the generation of replication competent viruses, all accessory 
genes (vif, vpr, vpu, and nef) are removed from (or mutated in) the packaging plasmids in 
second-generation lentiviral vectors (B). In third-generation lentiviral vectors, the 
enhancer/promoter unit is deleted from the U3 region of the 3’ LTR (∆U3) in transfer vector 
plasmids (SIN vector). Additionally the U3 region of the 5’ LTR is replaced with the CMV 
promoter, enabling Tat-independent production of the lentiviral vectors (C). LTR, long 
terminal repeat; ψ, packaging signal; RRE, Rev response element. 
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3.2 Second-generation lentiviral vectors 
The second-generation lentiviral vectors basically employ a similar three-plasmid system as 
the first generation vectors. Yet, in order to overcome the safety issue attributable to the 
first-generation vectors, the second-generation lentiviral vectors were generated without 
production of all accessory proteins (Vif, Vpr, Vpu, and Nef) via mutation or deletion of 
these genes from the packaging plasmid (Gasmi et al., 1999; Kim et al., 1998; Zufferey et al., 
1997) (Fig. 3B).  
3.3 Third-generation lentiviral vectors 
The second-generation vectors, however, still carry the transcriptionally active LTR 
elements that could induce the homologous recombination between the vector genome and 
wild-type HIV-1. This would be particularly problematic if the lentiviral vectors are used for 
gene therapy of HIV/AIDS. Thus, further improvements were made in the third-generation 
lentiviral vectors. To minimize the transcriptional activity of the LTR in transduced cells, the 
enhancer/promoter unit was deleted from the U3 region of the 3’ LTR in transfer vector 
plasmids. During reverse transcription in the transduced cells, this deletion is transferred to 
the 5’ LTR of the lentiviral DNA, thereby reducing promoter activity of the integrated 
provirus (self-inactivating [SIN] vector) (Miyoshi et al., 1998; Zufferey et al., 1998). 
Additionally, the U3’region of the 5’ LTR in the transfer vector plasmid was replaced with 
the cytomegalovirus (CMV) promoter, which enabled Tat-independent transcription of the 
lentiviral vector genome in producer cells (Dull et al., 1998; Miyoshi et al., 1998). In these 
SIN vectors, there is no compete HIV-1 U3 sequence. Moreover, expression of Rev protein is 
directed by a separate plasmid, but not by the packaging plasmid encoding gag and pol 
genes (Wagner et al., 2000) (Fig. 3C). Currently, third-generation SIN lentiviral vector 
system offers the best safety profile in terms of generation of RCL because this vector 
requires only three HIV-1 genes (gag, pol, and rev) for production, however safety 
improvement in the design of HIV-1-derived lentiviral vectors is still one of the challenging 
areas in gene therapy study 
4. Incorporation of regulatable gene expression systems in HIV-1-derived 
lentiviral vectors 
Lentiviral vectors hold great promise for a gene therapy approach to inherited and 
acquired diseases. In these particular clinical settings, it would be more beneficial to 
reversibly control transgene expression in a dose and time dependent manner as 
illustrated in the field of angiogenesis and Parkinson’s disease (Ma et al., 2002; 
Yancopoulos et al., 2000). To meet the standards required for clinical applications, a 
number of regulatable gene expression systems have been developed, and some of them 
are indeed incorporated into viral vectors including HIV-1-derived lentiviral vectors 
(reviewed in Goverdhana et al., 2005). 
Although early development of the regulatable gene expression systems was based on 
naturally occurring inducible cellular promoters that respond to exogenous signals, these 
types of systems had limitations due to the pleiotropic effects of the inducer, high levels of 
“leaky” background expression and poor performance in inducibility. Therefore, recent 
efforts have been mostly focused on the development of chimeric gene regulatable systems 
derived from prokaryotic, eukaryotic, and viral elements, which are designed to enhance 
specificity and activity of transgene expression (Fussenegger, 2001). 
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4.1 Tetracycline-regulated system 
The most widely used inducible system in lentiviral vectors is the tetracycline (Tet)-
regulated system. This system was originally based on binding of the Tet-controlled 
repressor (tetR), a 23.6 kDa protein of Escherichia coli (E. coli), to the operator sequence of E. 
coli Tet resistance gene (Baron & Bujard, 2000), but further developed to be operated in 
mammalian cells by the generation of a chimeric protein in which tetR is fused with herpes 
simplex virus (HSV) VP16 protein, a eukaryotic transactivator (Tet-controlled transactivator: 
tTA) (Gossen & Bujard, 1992). In the absence of Tet or its derivatives such as doxycycline 
(Dox), the tTA binds the Tet-response element (TRE) that is composed of seven tandem 
copies of Tet operator (tetO) sequences and placed upstream of the CMV minimal promoter 
(Baron & Bujard, 2000). This type of original Tet-regulated system, called Tet-off system, has 
been incorporated into HIV-1-derived lentiviral vectors (Gascon et al., 2008; Haack et al., 
2004; Kafri et al., 2000; Vigna et al., 2002) (Fig. 4A). In the first study that employed the Tet-
off system in the context of a lentiviral vector, transgene induction by the withdrawal of Dox 
resulted in a more than 500-fold increase in the expression level of a GFP reporter gene 
(Kafri et al., 2000). Of note, the Dox-dependent regulation of GFP expression was also 
confirmed in the brain cells of rats that had been transduced by the lentiviral vector and 
then administered Dox through drinking water, indicating applicability of the gene 
regulatable lentiviral vectors in vivo (Kafri et al., 2000). However, even in the presence of 
Dox, high levels of basal GFP expression was observed, which would be attributed to the 
transcriptional interference arising from the neighboring CMV promoter or the wild-type 
HIV-1 LTR. 
In addition to the background activity in the repressed state, the major limitation of the Tet-
off system is the requirement of continuous administration of Tet or Dox to suppress 
transgene expression. To overcome this limitation, another type of Tet-controlled gene 
expression system was established by introduction of several permutations in the tTA 
protein of the Tet-off system. The mutant tTA binds the tetO sequences only in the presence 
of Tet/Dox: it exhibits opposite function (Gossen et al., 1995). Because this modified version 
of regulatable system, the so-called Tet-on system, shows rapid kinetics of gene 
upregulation compared to Tet-off system, several HIV-1-derived lentiviral vectors have been 
constructed using the Tet-on system as well (Johansen et al., 2002; Koponen et al., 2003; 
Pluta et al., 2005; Reiser et al., 2000; Vogel et al., 2004) (Fig. 4B). 
One more approach to permit tight control of transgenes in the context of a lentiviral vector 
is demonstrated in the Tet-regulated system that employs a chimeric tetR fused with the 
Krüppel-associated box (KRAB) domain, a transcriptional regulator found in many DNA 
binding zinc-finger proteins (Szulc et al., 2006; Wiznerowicz & Trono, 2003). Binding of the 
KRAB domain-containing repressor protein to DNA recruits various heterochromatin-
inducing factors, thereby suppressing activity of cellular RNA polymerases (RNAPs) II and 
III. This transcriptional silencing can be exerted no farther than 2-3 kb away from the 
repressor binding site. In the new design of Tet-regulated lentiviral vector system, the tetO 
site was inserted upstream of the RNAP III promoter-driven small hairpin RNA (shRNA) 
expression cassette which was located in the U3 region of lentiviral vector genome, and the 
activity of tetO-linked shRNA expression unit was tightly suppressed in the presence of 
KRAB-fused tTA and in the absence of Dox. The KRAB-fused tTA/Dox-dependent 
inhibition of transcriptional activity was also observed in the internal RNAP II promoter for 
a reporter transgene within the same vector genome. However, when the transduced cells 
were treated with Dox, shRNA was produced to achieve RNA interference, which was 
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correlated with the expression of the reporter transgene (Szulc et al., 2006; Wiznerowicz & 
Trono, 2003). 
One drawback of the Tet-regulated system is that there is a requirement to deliver two distinct 
expression units into a target cell: one is for transactivator (e.g. tTA) expression and the other is 
for transgene expression. In a binary lentiviral vector approach in which tTA and transgene 
expression cassettes are cloned into separate vectors, a population cells that is singly 
transduced with either tTA or transgene would be produced, resulting in low inducibility as a 
whole. This can be a bottleneck, particularly in relevant applications of the Tet-regulated 
lentiviral vector systems in clinical use. Single vector systems that contain the entire 
regulatable component in a unique vector is one of the solutions to guarantee simultaneous 
expression of the two expression units in the target gene, and these have indeed been 
established (Gascon et al., 2008; Kafri et al., 2000; Szulc et al., 2006; Vogel et al., 2004). 
4.2 Mifepristone-inducible system 
This gene regulatable system (also called GeneSwitch system) is based on a mutated human 
progesterone receptor that responds to the synthetic progestin antagonist but fails to bind 
natural progestins or other steroids (Burcin et al., 1999; Wang et al., 1994). Similar to Tet-
regulated system, this system requires two components: the regulator (transactivator) 
protein and the inducible promoter sequence that drives transgene expression. The 
regulator is a hybrid protein consisting of a GAL4 DNA-binding domain from Saccharomyces 
cerevisiae, a ligand-binding domain of mutant progesterone receptor, and an activation 
domain of the p65 subunit of human NF-κB (Burcin et al., 1999). The inducible transgene 
expression unit contains six copies of the GAL4 upstream activating sequences (UAS) and 
the TATA box sequence in its promoter (Abruzzese et al., 1999). The progestin antagonist 
commonly used as an inducer for the GeneSwitch system is mifepristone (MFP, RU486). The 
regulator protein initially exists as an inactive monomeric form. However, in the presence of 
MFP, it binds to the MFP and undergoes a conformational change, causing the regulator 
protein to become an active homodimer. The active form of the regulator is able to bind to 
GAL4 UAS and induce transgene expression (Nordstrom, 2003) (Fig. 4C). 
Sirin and Park have incorporated the MFP-inducible gene expression system into HIV-1-
derived lentiviral vectors (Sirin & Park, 2003). In their design, two different SIN lentiviral 
vectors were constructed, in which either the regulator protein expression unit or the 
inducible transgene expression unit was cloned. When human cell lines (HeLa and Huh7 
cells) were infected with both lentiviral vectors, up to a 275-fold increase in the number of 
reporter fluorescent protein-positive cells was observed at 48 hours following MFP 
treatment. Similar effective induction was also detected in cells transduced by a lentiviral 
vector expressing the human α1-antitrypsin (hAAT) with an extremely low level of basal 
hAAT expression (Sirin & Park, 2003). 
Although an in vitro study using adenovirus vector expressing the chloramphenicol acetyl 
transferase (CAT) as a reporter transgene gene demonstrates that induction level of the 
GeneSwitch system is lower than that of the Tet-regulated (Tet-on) system (Molin et al., 
1998), the GeneSwitch system holds some advantages in its application to human gene 
therapy. The majority of components of the regulator protein are derived from human 
proteins, which has less impact on cell viability and immunogenicity. In addition, MFP has 
been approved by the Food and Drug Administration (FDA) for use in humans (Ulmann et 
al., 1995), and the concentration of MFP need for transgene induction is significantly lower 
than the concentration for its anti-progesterone effect (Nordstrom, 2003).  
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Fig. 4. Diagrams of two regulatable gene expression systems. The Tetracycline-regulated 
system is the most widely used inducible system in lentiviral vectors. In a Tet-off system 
(A), the Tet-controlled transactivator (tTA), a chimeric protein of E. Coli Tet-controlled 
repressor (tetR) and HSV VP16, binds the Tet-response element (TRE) upstream of the CMV 
promoter in the absence of Tet or Dox. On the other hand, in the Tet-on system (B), several 
mutations are introduced into the tTA (rtTA) so that this transactivator binds the TRE in the 
presence of Dox. The Mifepristone-inducible system (GeneSwitch) has been also 
incorporated into HIV-1-derived lentiviral vectors. In this system, the transactivator is a 
chimeric protein that comprises the GAL4 DNA-binding domain from Saccharomyces 
cerevisiae fused to the ligand-binding domain of a mutant progesterone receptor (hPR LBD 
∆19) and the activation domain of the p65 subunit of human NF-kB. In the presence of 
mifepristone (MFP), the chimeric transactivator binds to the six copies of GAL4 upstream of 
the activating sequences and induce transgene expression (C). TATA, TATA box sequence. 
4.3 Ecdysone-regulated system 
The Drosophila melanogaster ecdysone receptor (EcR)-based gene regulatable system has been 
adapted to lentiviral vectors (Galimi et al., 2005). EcR is a member of the nuclear receptor 
superfamily that mediates a cascade of morphological changes in Drosophila, triggered by 
the steroid hormone ecdysone. Ecdysone regulates gene expressions by interacting with the 
functional EcR, which in turn induces binding of the EcR to DNA regulatory elements 
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EcREs) near target genes (No et al., 1996). The ecdysone-regulated gene expression system 
incorporated into lentiviral vectors employed two elements: i) the dimeric regulator protein 
of the EcR fused with HSV VP16 activation domain (VgEcR) and the retinoid X receptor 
(RXR), and ii) the hybrid promoter between the glucocorticoid response element and that of 
type II nuclear receptors (E/GRE) (Galimi et al., 2005). Upon exposure to ecdysone or 
synthetic analogues such as ponasterone A, the VgECR/RXR heterodimer binds to the 
E/GRE, resulting in induction of transgene expression (Saez et al., 2000). One advantage of 
the ecdysone-regulated gene expression system is the pharmacological profile of the inducer 
that allows for fast distribution and clearance after administration in vivo (Saez et al., 2000). 
Additionally, the inducible promoter is not responsive to natural nuclear receptors (No et 
al., 1996). 
In the single vector approach, the inducible GFP expression cassette containing E/GRE as 
well as a CNV promoter-driven bicistronic unit for VgEcR and RXR expressions were cloned 
into an HIV-1-derived SIN lentiviral vector. However, this ecdysone-regulated system was 
also applicable to the binary vector system, in which the VgEcR/RXR expression unit was in 
one lentiviral vector and the inducible transgene expression unit was in the second vector. 
The latter approach would be of value in deliver of longer transgene. These lentiviral vectors 
have been shown to successfully deliver the ponA-inducible GFP expression units in vitro 
and ex vivo (Galimi et al., 2005). 
4.4 Other regulatable systems 
Besides the Tet- MFP-, and ecdysone-regulated systems, different types of inducible 
lentiviral vectors have been generated based on the other chimeric regulatable systems, 
which include streptogramin-adjustable expression system derived from Streptomyces 
coelicolor (Mitta et al., 2004) and gaseous acetaldehyde-inducible expression system derived 
from Aspergillus nidulans (Hartenbach & Fussenegger, 2005). Although some endogenous 
cellular elements that respond to exogenous signals or stress have been adapted to HIV-1- 
and EIAV-derived lentiviral vectors (Beutelspacher et al., 2005; Hurttila et al., 2008; Parker et 
al., 2009), the pleiotropic effects exerted by the inducing agent would be a drawback in a 
human therapeutic context (Fussenegger, 2001). 
5. Application of a gene regulatable lentiviral vector for HIV-1 inhibition 
Lentiviral vector-mediated gene therapy has the potential to improve the clinical state of a 
patient with HIV-1. This goal would be accomplished by ex vivo transduction of anti-HIV 
genes into CD4+ virus target cells such as helper T cells and macrophages or CD34+ 
progenitor cells (HSCs), making them resistant to HIV-1 infection (intracellular 
immunization approach) (Baltimore, 1988; Kitchen et al., 2011). So far, various studies have 
reported the delivery of anti-HIV genes by HIV-1-based lentiviral vectors in vitro and in vivo, 
and the anti-HIV genes can be categorized as either RNA- or protein-based (Mukhtar et al., 
2000) (Banerjea et al., 2003; Dropulic et al., 1996; Klimatcheva et al., 2001; Li et al., 2003; 
Mautino et al., 2001; Mautino & Morgan, 2002a, b, c). Among the RNA-based anti-HIV genes 
include a ribozyme that cleaves the U5 region of HIV-1 RNA by its enzymatic activity 
(Dropulic et al., 1996), an antisense RNA that hybridizes the transcripts of HIV-1 env gene to 
inhibit translation of Env (Mautino & Morgan, 2002a, c), and small interfering RNA (siRNA) 
that induces sequence-specific degradation of HIV-1 RNA (Banerjea et al., 2003). In the 
protein-based approach, the transdominant negative mutant of Rev (TdRev) is best 
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described as an anti-HIV gene used in the setting of lentiviral vectors (Klimatcheva et al., 
2001; Mautino et al., 2001; Mautino & Morgan, 2002c; Mukhtar et al., 2000). The TdReV 
named RevM10 is a derivative of HIV-1 Rev in which two amino acid mutations are 
introduced in the C-terminus activation domain, and hampers nuclear export of HIV-1 
mRNAs via the formation of inactive multimers with WT Rev (Hope et al., 1992; Malim et 
al., 1989). It should be noted that RevM10 has been already tested in phase I clinical trials to 
treat HIV infection via transduction of the gene into CD34+ cells with MoMLV-derived 
retroviral vectors (Kang et al., 2002; Kitchen et al., 2011; Podsakoff et al., 2005). 
Although a promising approach for HIV gene therapy, constitutive expression of anti-HIV 
genes in the context of HIV-1-derived lentiviral vectors could encounter a problem of self-
inhibition of the vector particle production, resulting in significant decrease of viral 
infectious titer (Mautino & Morgan, 2002b). This problem of self-inhibition can be solved by 
several means. If the anti-HIV gene targets specific sequences in the HIV-1 RNA, one 
strategy to avoid the self-inhibition would be to engineer nucleotide sequences of lentiviral 
vector genome and packaging genes in order that anti-HIV gene will exclusively recognize 
wild-type virus in transduced cells. As for TdRev, the inhibition of vector production could 
be overcome by replacement of the HIV-1 Rev-dependent nuclear export element (e.g. RRE) 
with the one derived from another lentiviruses, conferring Rev-independent property on the 
lentiviral vectors (Mautino et al., 2001; Taylor et al., 2008). But, if the anti-HIV genes are 
designed to target HIV-1 at more fundamental process such as virion formation and 
budding processes, an ideal strategy would be the incorporation of regulatable transgene 
expression system into lentiviral vectors, in which expression of the anti-HIV gene is “OFF” 
during vector production and turned “ON” in the target cells. 
In order to assess the availability of gene regulatable systems in inhibition of HIV-1, we have 
generated HIV-1-derived lentiviral vectors harboring the MFP-inducible transgene 
expression unit (Shinoda et al., 2009). In the study, two SIN lentiviral vectors were designed 
to incorporate the MFP-inducible unit in either the forward or the reverse orientation with 
respect to the direction of transfer vector genome (designated as forward and reverse 
vectors, respectively), since it has been reported that promoter activity of the internal gene 
expression unit could be affected by its orientation and/or the presence of adjacent LTR 
(Chen et al., 1992; Reiser et al., 2000; Sirin & Park, 2003). When firefly luciferase gene, which 
does not interfere with HIV-1 production, was inserted into the MFP-inducible lentiviral 
vectors, substantial levels of infectious vectors could be yielded from the forward and 
reverse vector systems by co-transfection with packaging plasmid DNAs in HEK293T cells. 
However, the infectious titer obtained by the forward vector was more than 10-fold higher 
than reverse vector, and even in the absence of transactivator and inducer, significant level 
of the leaky expression of luciferase was observed in the forward vector plasmid 
transfected-cells, but not in the reverse vector-transfected cells (Shinoda et al., 2009). It can 
be speculated that the higher background activity in the forward vector was due to the 
enhancement of gene expression by orientation-dependent cis-acting element such as the 
woodchuck post-regulatory element (WPRE) and/or the weak promoter activity of the  
5’ LTR. Importantly, this tight suppression of inducible unit in the reverse vector was 
reflected in its ability to produce infectious vectors when a transdominant negative mutant 
of human VPS4B protein in the VPS pathway, which inhibits budding process of HIV-1, was 
used as a transgene. Transfection of the reverse vector plasmid containing VPS4B dominant-
negative mutant yielded infectious lentiviral vector, transfection of the forward vector could 
not generate infectious vectors, demonstrating the self-inhibition by the leaky expression of 
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VPS4B dominant-negative mutant from the forward vector plasmid in vector producing 
cells (Shinoda et al., 2009). As expected, subsequent transduction of the transactivator-
expressing cells with the infectious reverse vector bearing the VPS4B mutant resulted in 
significant inhibition of wild-type HIV-1 production only in the presence of MFP (Shinoda 
et al., 2009). Thus, this previous study demonstrates that the gene regulatable lentiviral 
vector system has the capability to transduce anti-HIV gene and subsequently block HIV-1 
budding without the problem of self-inhibition during vector production. 
6. Conclusion and future direction 
Lentiviral vectors derived from HIV-1 are attractive gene delivery vehicles in terms of stable 
and long-term transgene expression in dividing and non-dividing cells. Although strong 
promoters used to achieve high levels of transgene expression are put into general use in the 
lentiviral vectors, incorporation of regulatable gene expression system confers 
transcriptional flexibility to the vector, which expands the potential of the lentiviral vectors 
for a wide array of gene transfer applications, particularly when undesired side effect would 
be expected by the constitutive expression of transgene. Nevertheless, many obstacles must 
be overcome for the clinical application of gene regulatable lentiviral vectors in gene 
therapy. One of the obstacles is that all the components of a regulatory system should be 
incorporated into a single vector, limiting the cloning capacity for transgene. Another issue 
is that there is no gene regulatory system approved by the FDA for clinical use. However, if 
their safety and efficacy are validated, development of gene regulatable lentiviral vector 
systems will be a next promising step toward achieving successful gene therapy for 
otherwise incurable diseases. 
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